Skip to main content
GUTS logo

GUTS · Fractyl Health, Inc. · Webcasts, Transcripts & Audio

Track GUTS — free
$0.97 -0.11 (-9.92%) Play latest call Q3 2026 earnings call transcript
Market Cap
$12.67M
Shares
13.26M
Volume · Nov 19 223.24K Avg daily vol (34 sessions) 804.78K

Fractyl Health, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Fractyl Health, Inc. (GUTS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-12
Fractyl Health, Inc. (GUTS) November 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-12
Fractyl Health, Inc. (GUTS) Q3 2026 Earnings Call Transcript
Confident tone Revita pivotal efficacy 12-month data and future milestones CMS coverage and reimbursement
Diluted EPS
$-1.07
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
Fractyl Health, Inc. (GUTS) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Fractyl Health, Inc. (GUTS) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-10
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Confident tone Revita pivotal trial readout (Remain 1) GLP-1 market dynamics and off-ramp thesis Regulatory pathway and FDA engagement
Diluted EPS
$-1.92
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-14
Fractyl Health, Inc. (GUTS) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Confident tone IP portfolio Pivotal trial execution (Remain One) GLP-1 market dynamics and post-GLP-1 rebound
Diluted EPS
$0.72
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Confident tone Revita dose-response (ablation length) REMAIN-1 pivotal study design and readout timeline Regulatory pathway and FDA feedback
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Confident tone Revita Clinical Data and Durability Remain 1 Pivotal Trial Progress Upcoming Clinical Catalysts and Regulatory Path
Diluted EPS
$-8.46
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
Confident tone Revita / REMAIN-1 pivotal study and randomized readout Weight regain after GLP-1 discontinuation (unmet need) German real-world registry durability data
Diluted EPS
$-6.84
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Confident tone Remain-1 pivotal enrollment completion Rejuva / RJVA-001 gene therapy platform GLP-1 efficacy and durability gap
Diluted EPS
$-5.88
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
Confident tone Revita / REMAIN-1 pivotal study in weight maintenance Rejuva gene therapy platform REVEAL-1 open-label early data
Revenue
$3,000*
▼ 57.1% YoY
Gross margin
100.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
Confident tone GLP-1 limitations and durability concerns Rejuva gene therapy platform and preclinical data Revita REMAIN-1 pivotal study for weight maintenance
Revenue
$14,000
▼ 61.1% YoY
Diluted EPS
$-5.76
Gross margin
50.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
Positive tone Revita Breakthrough Device Designation REMAIN-1 Weight Maintenance Study Rejuva Gene Therapy Platform
Revenue
$43,000
▼ 40.3% YoY
Diluted EPS
$-4.32
Gross margin
44.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Confident tone Revita Remain-1 Pivotal Study in Obesity Revitalize-1 Pivotal Trial in Type 2 Diabetes Rejuva Gene Therapy Platform / RJVA-001
Revenue
$33,000
▲ 560% YoY
Diluted EPS
$-2.04
Gross margin
42.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 webcasts
Key facts CIK 1572616 CUSIP 35168W202 13F (30d) 87 filings 72 filers Visit website Investor relations